
Operations Office

Telephone (507) 284-2172



Date: May 19, 2006

To: NCCTG Primary Clinical Research Associates

From: Patricia A. Mann
Protocol Development Coordinator

Re: N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR[®] Depot) for Symptomatic Ascites in Cancer Patients

The eligibility checklist has been revised. The “Assigned Treatment” section now has lines for entering the name and phone number of the contact person for the study. A randomization specialist will call the contact person with the treatment assignment for the patient.

Please call or e-mail me at mann.patricia@mayo.edu if you have any questions.